HEALTH TECHNOLOGY

Annuo Med Tech Solutions Enters Partnership Agreement with WeKo GP

Annuo Medical Technology Solutions Pty Ltd | October 17, 2022 | Read time : 01:00 min

Annuo Med

New health networking platform, Annuo™, has entered a working agreement with WeKo GP to assist with the identification and treatment of patients with chronic disease in Australia.

This key partnership will facilitate the management of people living with chronic disease by General Practice teams using WeKo and Annuo™.

WeKo’s Clinical System solution launched in 2019 and provides proactive chronic disease screening and detection based on patient medical data.

“We believe our solutions are highly complementary and have the ability to offer an amazing patient and clinician experience,” commented WeKo Founder, Ross Hadfield.

We are excited to announce a trial partnership between Annuo and WeKo GP which will open up more possibilities for Annuo™ to help the 10.8M Australians currently living with chronic disease,”

Dr Jeni Wellington, Founder and CEO of Annuo Med Tech Solutions

At a high-level, the partnership will facilitate the identification and treatment of patients at high risk of chronic disease, using the Annuo platform and WeKo’s Clinical System. It will ensure patients are engaged in the creation of an agreed care plan and that the clinical teams involved are fully supported.

About Annuo Med Tech

Annuo Med Tech Solutions is a new Australian digital health technology company developing Annuo - a healthcare networking platform for doctors, patients and allied health professionals. Annuo™, is the first medical networking platform in Australia designed by specialists.

More than that, Annuo™ is advocating for collaborative care for patients living with chronic disease in Australia. With 47% of Australians today living with one or more chronic diseases, there has never been a better time to help improve the lives of everyday people trying to navigate their treatment.

Annuo™ encourages people living with chronic disease to engage with their treatment in an holistic way. Annuo promotes collaborative care for patients and is inclusive of those seeking to make diet, exercise and alternate therapies as part of their treatment planning. Annuo™ will engage with healthcare providers and enable them to better connect with their patients through the digital health space. The platform comes fully customised for each medical specialty at a competitive price.

Spotlight

Every segment in health care is experiencing extraordinary changes in the workforce. Burnout, turnover, rising labor costs and skill gaps are diminishing the supply of qualified workers.

Spotlight

Every segment in health care is experiencing extraordinary changes in the workforce. Burnout, turnover, rising labor costs and skill gaps are diminishing the supply of qualified workers.

Related News

HEALTH TECHNOLOGY

ZS and Abacus Insights Partner to Bring Innovative Data and Analytics to Health Plans

ZS and Abacus Insights | November 30, 2022

As ZS continues to help health plans evolve and transform, the firm announced an investment in and partnership with Abacus Insights, a healthcare technology leader with a groundbreaking offering in data usability that rapidly accelerates the achievement of key health plan goals including efficiency, equity, health services and member outcomes. “At ZS, we believe the future of healthcare is connected, with providers, health plans, pharma companies and other stakeholders working together. Usable data from Abacus Insights is a key enabler and connecter, and we take seriously our role in helping health plans innovate and excel. Partnerships like this one between ZS and Abacus Insights will be increasingly important in a connected health ecosystem.” ZS CEO Pratap Khedkar Abacus Insights offers the capability to consolidate and clean billions of pieces of structured and unstructured data from payers, providers, labs, digital apps and many more sources, providing end users with complete, current and accurate data sets that drive both operational and analytical uses. Through this partnership, health plans working with ZS gain access to usable data and a full suite of analytics and digital tools, unlocking insights from sales to operations to health outcomes and accelerating a path to decisions and actions. “Abacus Insights is proud to have the support of ZS both as an investor and partner. ZS recognizes that data usability is a game-changer in creating and scaling big performance advances for health plans,” said Minal Patel, Abacus Insights CEO. “Our companies share a common purpose to improve healthcare. Our combined health plan-specific expertise will accelerate our ability to help clients achieve their key transformational goals of better serving their members and leading healthcare change.” Usable data from Abacus Insights is already powering better quality reporting, more accurate risk adjustment and improved value-based contracting, care and payments. ZS Managing Principal Adam Siskind, who leads the firm’s health plan and provider vertical, said the partnership aims to help unlock use cases that health plans can leverage to fully realize the benefits of their analytics transformations. “There is no shortage of health plan challenges to solve, and it seems there is never enough capacity to unravel them. Our partnership with Abacus Insights will help our clients access the solutions they need to not only reach their goals but to do so efficiently and with scale,” Siskind said. “At ZS, we are proud to be the leading firm at the intersection of healthcare and analytics, so it only made sense to join forces with Abacus Insights, a company already recognized as the leader in health plan data usability in the U.S. Our combined capabilities allow us to achieve a new level of impact that all of our health plan clients seek—and all of their members deserve.” About ZS ZS is a management consulting and technology firm focused on transforming global healthcare and beyond. We leverage our leading-edge analytics, plus the power of data, science and products to help our clients make more intelligent decisions, deliver innovative solutions and improve outcomes for all. Founded in 1983, ZS has more than 12,000 employees in 35 offices worldwide. About Abacus Insights Abacus Insights is a healthcare technology leader with the only data transformation platform and solutions built specifically for health plans. Focused on data usability, Abacus Insights gives payers a new level of control and flexibility with their data by developing accurate, timely, and robust ecosystems that can support analytics and operational use cases. Managing data for 21 million members, Abacus Insights partners with payers to deliver scalable solutions that drive strategic initiatives, control costs, and improve member lives and experiences.

Read More

HEALTHTECH SECURITY

Henry Ford Health and the PINC AI™ Applied Sciences Team Lead Action to Advance Health Equity

Henry Ford Health | November 21, 2022

Henry Ford Innovations one of the nation's leading healthcare innovation programs, recently hosted the inaugural "Advancing Health Equity Through Innovation and Collaboration" event in partnership with the PINC AI™ Applied Sciences team, a leading provider of advanced analytics, technology solutions and clinical research support services to the life sciences industry. The initiative's purpose was to turn health equity conversations into action by taking measurable steps towards improving the health of millions. Participants included global leaders in life sciences, as well as Henry Ford Health innovators who are already implementing programs to address health disparities in groups who have been historically marginalized and underrepresented. "Part of innovating is looking for partners to expand successful test programs and develop new ones. Partnerships like the ones we're forging with these corporate partners will create a true impact in addressing health equity. We are thrilled to have the opportunity to share our findings with national leaders in the life sciences and pharmaceutical industries and chart a path forward to bring these solutions to help more people." Lisa Prasad, Henry Ford Health's Chief Innovation Officer and leader of Henry Ford Innovations The two-day event in late October included a presentation of case studies from successful Henry Ford Health programs, including community-based partnerships to increase health screenings. That program found that a lack of trust in institutions can deter people from getting preventative care and that using community partners for healthcare services can reduce barriers and increase access to care. Other case studies covered programs to improve hypertension in young African American men and reduce infant mortality among underserved populations. The unique action-focused event allowed leaders from Henry Ford Health, the PINC AI™ Applied Sciences team and collaborators from eight global life sciences companies to meet, connect and work together on ways to amplify and expand pilot programs. "The impactful work Henry Ford Health already has under way makes Detroit an ideal location to look for solutions to reduce health inequities across the country," said Denise Juliano, Life Sciences Group Vice President, PINC AI™ Applied Sciences. "PINC AI™ Applied Sciences partners with leaders in healthcare to improve health outcomes and advance equitable care for all people. This initiative was a great step forward to accelerate our efforts to address the challenges of health inequities that continue to persist." Because of Henry Ford Health's community connections and its long-standing work to improve diversity, equity, inclusion and justice (DEIJ), the health system is a leader in researching and tackling health disparities in Detroit. In 2021, Henry Ford launched a new initiative to improve the representation of African American people in cancer clinical trials. It was an important collaboration, especially considering that recent research shows 85 percent of participants in clinical trials are white. Another program supported by HFI provides medical mentorship and internship opportunities for Detroit-based high school students. Both initiatives serve as examples of the meaningful change health and life sciences organizations can affect together. "This initiative is an example of how Henry Ford's commitment to DEIJ extends beyond ideas and connects directly to action," said Ikenna Okereke, M.D., Henry Ford Health's Vice Chair of Surgery and Director of Thoracic Surgery. "Through Henry Ford's Department of Surgery High School Mentorship Program, I've seen firsthand how programs that work in other communities can grow for a larger impact. I'm excited to be a part of the next chapter in creating more programs and initiatives to address health disparities." Henry Ford Health and the PINC AI™ Applied Sciences team will now work with the summit's participating partners to strengthen and scale solutions to advance health equity. About Henry Ford Health Serving communities across Michigan and beyond, Henry Ford Health is committed to partnering with patients and members along their entire health journey. Henry Ford Health provides a full continuum of services – from primary and preventative care, to complex and specialty care, health insurance, a full suite of home health offerings, virtual care, pharmacy, eye care and other healthcare retail. It is one of the nation's leading academic medical centers, recognized for clinical excellence in cancer care, cardiology and cardiovascular surgery, neurology and neurosurgery, orthopedics and sports medicine, and multi-organ transplants. Consistently ranked among the top five National Institutes of Health (NIH)-funded institutions in Michigan, Henry Ford Health engages in more than 2,000 research projects annually. Equally committed to educating the next generation of health professionals, Henry Ford Health trains more than 4,000 medical students, residents, and fellows every year across 50+ accredited programs. With more than 33,000 valued team members, Henry Ford Health is also among Michigan's largest and most diverse employers, including nearly 6,000 physicians and researchers from the Henry Ford Medical Group, Henry Ford Physician Network and Jackson Health Network. The health system is led by President and CEO Robert G. Riney and serves a growing number of customers across 250+ locations throughout Michigan including five acute care hospitals, two destination facilities for complex cancer and orthopedics and sports medicine care, three behavioral health facilities, primary care and urgent care centers. About the PINC AI™ Platform PINC AI™ is the technology and services platform of Premier Inc. With more than 20 years' worth of cost, quality and operational data gleaned from 45 percent of U.S. hospital discharges, 812 million hospital outpatient and clinic encounters and 131 million physician office visits, the PINC AI™ platform provides actionable intelligence to help improve outcomes, support improved financial performance and enable success in new, alternative payment models. PINC AI™ offerings rely on advanced analytics to identify improvement opportunities, consulting services for clinical and operational design, and workflow solutions to hardwire sustainable change. The PINC AI™ platform is also the data engine powering Premier's newest brands – Remitra™ and Contigo Health®.

Read More

FUTURE OF HEALTHCARE

Anumana and Pfizer Partner to Enable Early Detection of Underdiagnosed Cardiovascular Disease

Anumana | December 16, 2022

Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has entered into a multi-year agreement with Pfizer, Inc. for Anumana to develop an artificial intelligence electrocardiogram algorithm designed to enable the early suspicion of cardiac amyloidosis. Anumana will conduct a clinical validation trial and pursue De Novo classification for the algorithm as a Software-as-a-Medical-Device and aims to gain regulatory approval for the algorithm as an SaMD for the detection of cardiac amyloidosis in the U.S., Europe and Japan. Cardiac amyloidosis is a serious, progressive, and underdiagnosed rare disease that leads to heart failure.1 In patients with cardiac amyloidosis, the heart walls become stiff, making it difficult for the left ventricle to properly relax and fill with blood, while at the same time hampering its ability to squeeze and pump blood out of the heart. Symptoms and comorbidities associated with cardiac amyloidosis, such as shortness of breath, knee pain, bilateral carpal tunnel syndrome, kidney disease, and gastrointestinal issues, can vary and seem unrelated, making diagnosis difficult.2,3 “The challenge in diagnosing cardiac amyloidosis can prevent patients from getting treatment while the disease continues to progress. We believe this collaboration will demonstrate the power of Anumana’s AI-ECG algorithms to help clinicians intervene earlier, giving them greater ability to improve patient outcomes and prolong lives.” David McMullin, chief business officer of Anumana The research agreement with Pfizer will help deepen Anumana’s efforts to implement AI-enabled early detection software that can reveal signals from ECGs that humans cannot interpret. The ubiquitous nature of the painless, non-invasive 100-year-old ECG test gives AI-ECG algorithms the potential to reach a larger number of patients earlier. “AI-ECG solutions alert clinicians to humanly imperceptible patterns in ECG signals, providing an early warning for serious occult or impending disease,” said Paul Friedman, M.D., Chair of the Department of Cardiovascular Medicine at Mayo Clinic and Chair of Anumana’s Mayo Clinic Board of Advisors. “This stands to improve the lives of people with cardiac amyloidosis by improving the speed of triage and care of this group.” Anumana was founded in 2021 in collaboration with the Mayo Clinic Platform. Anumana has licensed Mayo Clinic AI-ECG algorithms for low ejection fraction, pulmonary hypertension, and hyperkalemia, all of which have received Breakthrough Device Designation from the U.S. FDA. These algorithms have been validated by over 75 peer-reviewed publications, including a first of its kind prospective clinical impact study on low ventricular ejection fraction that was published in Nature Medicine in 2021, and another first of its kind batch enrolled prospective clinical impact study that demonstrated the effectiveness of AI-ECG to screen for undetected atrial fibrillation in normal sinus rhythm that was published in The Lancet in 2022. About Anumana Anumana, an AI-driven health technology company and portfolio company of nference, is harnessing industry-leading AI and translational science to unlock the electrical language of the heart as never before. Anumana algorithms have been developed, trained, and validated using clinical data from Mayo Clinic and other leading institutions to detect hidden diseases using AI-ECG algorithms and to enhance and improve interventional procedures through real-time AI techniques. Multiple Anumana algorithms have received FDA Breakthrough Device Designation and are currently undergoing rigorous clinical trial validation. Anumana software devices are designed for real-world physician use, integrating into existing workflows at the point of care to reduce costs and enhance quality of life. Anumana algorithms are investigational medical devices and have not yet received regulatory approval or clearance.

Read More